Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Vaccine Issues Author: Staff Editor Last Updated: Jul 29, 2014 - 2:57:10 PM



Vaccine Against Tick-transmitted Disease

By Staff Editor
Jul 29, 2014 - 2:53:36 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - RICHMOND, Va. (July 29, 2014) - Virginia Commonwealth University School of Medicine researchers have made an important advancement toward developing a vaccine against the debilitating and potentially deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA).

During the past several years, experts have seen a steady rise in the incidence of human infections caused by tick-transmitted bacterial pathogens - making the need for a vaccine critical. Successful vaccine development hinges on knowing what to target to prevent disease, and the VCU team has identified three such proteins on the surface of the HGA agent.

HGA is caused by a bacterium called Anaplasma phagocytophilum. HGA is transmitted by the same ticks that transmit Lyme disease, and it is the second most-common tick-borne disease in the United States. Between 2003 and 2012, the number of cases reported to the Centers for Disease Control and Prevention increased more than sixfold. However, evidence indicates that many more cases go undocumented. The disease is also found in Europe and Asia and can affect dogs, cats, horses and sheep.

In a study, published in the August issue of the journal Cellular Microbiology, researchers report the discovery of a protein called A. phagocytophilum invasion protein A, or AipA, found on the surface of the bacterium. It is a key player in mammalian cell invasion. They identified the specific region of this protein that is necessary for infection.

Further, they discovered that AipA works together with two other previously identified A. phagocytophilum surface proteins, OmpA and Asp14, to enable the pathogen to optimally invade host cells.

"This is an important finding because it highlights that pathogens use cooperative, even redundant mechanisms to invade host cells," said lead investigator Jason A. Carlyon, Ph.D., associate professor and a George and Lavinia Blick Scholar in the Department of Microbiology and Immunology in the VCU School of Medicine.

"Based on these findings, an effective preventative or therapeutic approach would be best achieved by targeting all three factors, rather than just one. Our research is a promising lead towards vaccine development against granulocytic anaplasmosis and is a blueprint for developing prophylactic and therapeutic approaches against pathogens that use multiple surface proteins to infect," he said.

"Furthermore, we have determined that humans and animals make antibodies against AipA, OmpA, and Asp14 during granulocytic anaplasmosis, which means they could be used to develop effective diagnostic tests for the disease."

Carlyon is working with Richard T. Marconi, Ph.D., professor of microbiology and immunology in the VCU School of Medicine, to translate these findings into a vaccine against granulocytic anaplasmosis. A patent application has been filed and the technology is available for licensure. For further information, contact VCU Innovation Gateway [email protected].

This study builds on previously published work from the Carlyon lab. In 2012 and 2013, the team identified OmpA and Asp14, and determined that they worked together to promote A. phagocytophilum infection.

But, at that time, they also determined that a piece of the puzzle was missing.

"While using antibodies to target both did significantly reduce infection of host cells, the blocking was incomplete. This suggested to us the involvement of at least one additional Anaplasma protein, which, in this study, we identified as AipA," Carlyon said.

Next, the team will identify the key regions necessary for infection for surface proteins, OmpA and Asp14, and then validate whether targeting the regions of all three proteins prevents infection using a mouse model. According to Carlyon, the information could be used to develop a "trifecta vaccine" to target the relevant regions of the three proteins, and thereby provide effective protection against infection.

The findings are highlighted as the Editor's Choice in the August print issue of the journal Cellular Microbiology.

The study, titled "Anaplasma phagocytophilum surface protein AipA mediates invasion of mammalian host cells," appeared online on April 3.

Read the study abstract here: http://onlinelibrary.wiley.com/doi/10.1111/cmi.12286/abstract.

Carlyon collaborated with researchers from VCU, University of California at Davis and Yale University.

This work was supported by the National Institutes of Health grants R01 AI072683, R01 AI67830, and R01 AI141440; and the United States Department of Commerce Economic Development Administration. The VCU Flow Cytometry and Imaging Shared Resource Facility is supported in part by funding from NIH-NCI Cancer Center support grant 5P30 CA016059.


###


About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-seven of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University comprise the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.

###

For ad rates, call Mike McCurdy at 877-634-9180 or email at [email protected]  We have over 7,000 journalists who are subscribers.



Top of Page

HealthNewsDigest.com

Vaccine Issues
Latest Headlines


+ Protect Your Health and Get Vaccinated
+ Most U.S. Women Believe They Are Not Up To Date on Vaccinations
+ Get Vaccinated: Flu is Bigger Threat to You than Ebola
+ Study Vaccine For Hospital-Acquired Infections
+ Adults 65 And Older Should Understand Flu-Related Risks And Their Vaccination Options
+ U.S. Infant Vaccination Rates High
+ Vaccine Against Tick-transmitted Disease
+ Novartis Begins Shipment of Seasonal Influenza Vaccines to US Market for the 2014-2015 Season
+ Personalized Brain Tumor Vaccine Helps Patients Live Longer
+ International Vaccine Institute Launches New Video Marketing Campaign, 'Choose Your World'



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions